BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: However, a recent report showed that despite survivin being quite expressed in CD34+ cells, its levels are low in more precursor leukemia stem cells [138], indicating that survivin is not an optimal therapeutic target for CML stem cells compartment and suggesting that it may not be the main factor accounting for resistance to targeted therapy in CML [139].